Fresh analysis reveals that patients who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who end traditional lifestyle programs.
Findings released in a prominent medical journal points out that while overweight individuals frequently drop about a fifth of their body weight while on the medication, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"Individuals purchasing such medications should be informed of the risk of fast weight regain when the medication ends," warns researcher Dr. Susan Jebb.
That rate of regain suggests a reversion to pre-treatment weight within about a year and a half.
Analyzing Therapies
The study, which examined dozens of studies involving thousands of participants, compared the effects of the injectable medications with conventional dieting.
Researchers emphasize that individuals who lose weight through dieting generally see a more gradual creep back—perhaps 0.1 kg a month—once they finish.
The Reason for the Fast Rebound
Nutrition scientists propose the mode of action of the jabs accounts for the amplified weight return.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of GLP-1 levels several times higher than the body's typical production might result in the system to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication leads to appetite is uncontrolled, making overeating a significant risk."
A Lifelong Issue?
Health authorities suggest the injections for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
Many experts contend that, due to the likelihood of relapse, the treatment is often ongoing.
This opinion is supported by pharmaceutical companies, who say that the findings "highlight the persistent character of obesity," comparing it to managing conditions like diabetes.
User Testimonies
Individuals who have stopped the jabs explain a sudden resurgence of cravings.
"It felt as if something that goes on and you become ravenous," described an individual.
This difficulty is compounded if individuals have not adopted sustainable dietary or behavioural changes during therapy.
Widespread Use
Survey data suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is greater among women compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Ultimately, experts emphasize that while these medications are potent agents for weight loss, they are not a standalone fix and long-term success hinges on ongoing lifestyle changes.
